Novo Nordisk inks multimillion-dollar deal with Ventus Therapeutics

The Danish pharmaceutical firm gains exclusive worldwide rights to a number of treatment candidates, one of which is for fatty liver disease NASH, developed by the US-based biotech company.

Photo: Stine Tidsvilde

Danish pharmaceutical giant Novo Nordisk has signed a development and license agreement with Ventus Therapeutics, a US-based biotech focused on using small molecules to treat challenging targets, the latter firm announces in a press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs